Heidrun Engler et al. ·

Application No.: 08/889,355

Page 2

wherein:

n is an integer from 2-8;

 $X_1$  is a cholic acid group or deoxycholic acid group; and  $X_2$  and  $X_3$  are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, and hexose-pentose disaccharide groups;

and wherein at least one of  $X_2$ /and  $X_3$  is a saccharide group.

22. (Amended) A pharmaceutical composition comprising a mucoadhisive and a

therapeutically effective amount of a therapeutic agent formulated in a buffer comprising a

compound of Formula I:

4

2

5 wherein:

6 7

8

9

10

11

12

13

*n* is an integer from  $\frac{7}{4}$ -8;

X<sub>1</sub> is a cholic acid group or deoxycholic acid group; and X<sub>2</sub> and X<sub>3</sub> are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, and hexose-pentose disaccharide groups;

and wherein at least one of  $X_2$  and  $X_3$  is a saccharide group.

Application No.: 08/889,355

Page 3

35. (Amended) A method of treating bladder cancer comprising administration to a cell of a therapeutically effective amount of a therapeutic gene that is formulated in a buffer, wherein the therapeutically effective amount of a therapeutic gene is in the range of about from 1x10<sup>8</sup>

4 particles/ml to 5x10<sup>11</sup>-particles/ml of a recombinant adenovirus in which the therapeutic gene is

5 inserted, comprising a compound of Formula I:

6 7

wherein:

n is an integer from 2-8;

> 9

10

11

12

13

14

15

1

2

3

4

5

X<sub>1</sub> is a cholic acid group of recoxycholic acid group; and X<sub>2</sub> and X<sub>3</sub> are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, and hexose-pentose disaccharide groups;

and wherein at least one of  $X_2$  and  $X_3$  is a saccharide group.

36. (Amended) A method of treating bladder cancer comprising administration to a cell of a therapeutically effective amount of a therapeutic gene that is formulated in a buffer, wherein the therapeutically effective amount of a therapeutic gene is in the range of about from  $1x10^9$  particles/ml to  $5x10^{11}$ -particles/ml of a recombinant adenovirus in which the therapeutic gene is inserted, comprising a compound of Formula I:

$$X_1$$
  $C$   $HN$   $(CH_2)_n$   $N$   $(CH_2)_n$   $NH$   $C$   $X_3$   $C$   $C$   $X_2$ 

6 7

wherein:

8

n is an integer from 2-8;